Erectile dysfunction in heart disease patients

Area of Science:

• Cardiology
• Urology
• Sexual Medicine

Background:

• Atherosclerosis affects both coronary and penile arteries, contributing to erectile dysfunction (ED) in heart disease patients.
• ED in these patients is multifactorial, involving organic, psychological, and pharmacological causes, including medications for cardiovascular conditions.
• The incidence of ED post-myocardial infarction is significant, ranging from 38% to 78%.

Purpose of the Study:

• To assess the cardiovascular risk associated with sexual activity in heart disease patients.
• To establish guidelines for managing erectile dysfunction in patients with cardiovascular disease.
• To determine appropriate treatment strategies for ED in this population.

Main Methods:

• Evaluation of cardiovascular risk through medical history, echocardiography, and stress testing (Bruce protocol).
• Assessment of energy expenditure during sexual intercourse (3.7-5 METs).
• Review of contraindications and recommendations for oral ED treatments.

Main Results:

• Sexual intercourse requires moderate energy expenditure (up to 5 METs), generally considered safe for patients with a functional capacity exceeding 7 METs (achieved by completing two stages of the Bruce protocol).
• Sildenafil is recommended as a first-line oral therapy for ED in heart disease patients when sexual activity is not contraindicated.
• Specific contraindications and treatment recommendations are discussed.

Conclusions:

• Sexual activity can be safely undertaken by many heart disease patients with ED, provided cardiovascular risk is assessed.
• Oral sildenafil is a viable and effective treatment option for ED in stable heart disease patients.
• A comprehensive approach integrating cardiovascular assessment and appropriate ED pharmacotherapy is crucial.